Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
ConditionUlcerative Colitis (UC)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXencor, Inc.
About this trial
Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
Eligibility criteria
Qualifiers
Age 18-55
Must be in good health with no significant medical history
Clinical laboratory values within normal range
BMI 18-35 (inclusive)
Disqualifiers
Any physical or psychological condition that prohibits study completion
History of suicidal behavior or suicidal ideation
Heavy use of nicotine containing products
HIV, hepatitis B and hepatitis C positive
Trial design
Treatments tested in this trial
- XmAb942
- Placebo
Treatment groups
270 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov